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Plasma free, sulfo- and glucuro-conjugated catecholamines in uremic
patients. The metabolism of catecholamines (CA) in non-selected pa-
tients with chronic renal failure and under hemodialysis (CRFh) was
studied by mcasuring the concentration of plasma free, sulfo- and
glucuroconjugated CA, dopamine (DA), norepinephrine (NE), and
epinephrine (EPT). Our data demonstrate a statistically significant
increase of free DA and free NE concentration in CRFh, while that of
free EPI was not different from controls. However a careful scrutiny of
35 individual data suggests that sub-groups of patients with either high
normal or low plasma—free NE concentration could exist; this likely
heterogeneity could be a good explanation for conflicting conclusions
provided by previous reports. Suspecting that conjugated CA might be
altered in CRFh, plasma sulfa- and glucuro-conjugated DA, NE and
EPI were also measured. We have found a predictable and highly
significant increase of sulfa-conjugated CA; plasma concentration of
glucuro-conjugated DA and NE in CRFh was not different from
controls, while that of glucuro-conjugated EPI was significantly in-
creased. The physiological meaning, if any, of these new observations
on conjugated CA cannot be assessed at the moment. The effects of
hemodialysis were also investigated. Measurements on the arterial and
on the venous line showed highly significant differences for tyrosinc,
free and sulfa-conjugated CA, and a lack of difference for glucuro-
conjugated CA. Thus tyrosine, free and sulfa-conjugated CA were
eliminated by the artificial kidney, hot not glucoro-conjugated amines.
Furthermore, the hemadialysis—induced lasses of tyrosine were about
200-fold greater than those of CA, suggesting that hemodialysis is likely
to have a double series of effects on CA metabolism by reducing: a)
their circulating level, and b) the amount of tyrosine available, and thus
the amount of CA synthesized. Hemodialysis during a two hour period
of time was associated with no change in arterial concentration of
tyrosine and free CA, while that of DA sulfate and NE sulfate was
significantly decreased; an interpretation is tentatively proposed.
assessed by means of plasma concentrations of catecholamines
(CA), Unfortunately, measurements of norepinephrine (NE)
concentrations have provided conflicting conclusions in pa-
tients with chronic renal failure on hemadialysis (CRFh). An
increase has been reported by several groups [1—61, and not
confirmed by others 17—10]. As a matter of fact, there is a basic
disagreement on whether an adrenergic dysfunction exists in
these patients [1, 6, 7, 11—14]. On the contrary, it seems well
established that the activity of plasma dopamine—heta—hydrox-
ylase is decreased in CRFh [4, 5, 10, 15, 16]. This decrease is
apparently in contradiction with the increase of plasma NE
concentration, when reported [1—6], except if one considers the
decrease of this enzymatic activity as a reflection of an adrenergic
insufficiency, and the increase of plasma NE concentration as a
consequence of an incomplete filtering by the artificial kidney.
The present study was undertaken to forther investigate the
metabolism of catecholamines in CRFh, with three working
hypotheses: I) data on plasma NE concentrations were usually
obtained in small groups of patients, and they are conflicting
because they cover different segments of an heterogenous
population; 2) plasma sulfo-conjugated, and to a certain extent
glucuro-conjugated CA were worth measuring because sulfo-
conjugation is partly under the control of the sulfate reserve
pool [17], and because plasma sulfate concentration is very
much increased in CRFh [18]; 3) it is important from a
physiopathological point of view to have complete information
on both quantitative and qualitative effects of hemodialysis on
circulating CA.
The autonomic nervous system has a major role in the
regulation of blood pressure; whether its dysregulation can be
involved in the development and/or the maintenance of hyper-
tension remains an unanswered question. This is of a particular
interest in patients with chronic renal failure because they are
usually hypertensive before, and frequently normotensive when
treated by hemodialysis, and because their circulatory homeo-
stasis is regularly challenged by subtractions of extracellular
fluid volume.
The activity of the autonomic nervous system is usually
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Methods
Investigated subjects
All patients regularly hemodialyzed in the Hemodialysis
Center of Hopital Ambroise—Paré were volunteers, and have
participated in the first study. This was 35 non-selected CRFh
(15 women, 20 men); their mean age was 54.9 (range 24 to 74),
and they had been on regular hemodialysis for an average of
43.5 months (range Ito 117). The main causes of their chronic
renal insufficiency are listed in Table 1. On the day of blood
sampling for CA measurement, the mean plasma creatinine
concentration was 105.6 mg/liter (sEM = 3.7). Eighteen patients
were normotensive (mean blood pressure = 129/70 mm Hg),
while 17 presented a moderate hypertension (165/91 mm Hg);
hypertensive patients were given various antihypertensive
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Cause N
Chronic glomerulonephritis 10
Interstitial nephropathy 8
Vascular nephropathy 7
including 3 diabetics
Congenital nephropathy 4
Other 6
drugs (the last dose was taken about 18 hours before blood
sampling in 11 out of 17 patients), but no difference was
observed between normotensive and hypertensive groups of
patients as far as their mean concentrations of CA were
concerned. A residual diuresis was present in 15 patients and
absent in 20. They were hemodialyzed on the basis of three
times, four hours a week.
Data obtained in these 35 patients were compared to those
obtained in 18 men (N = 39 tests) and in 17 women (N = 31
tests), in apparent good health, whose mean age was 27.9 years
(range 21 to 49). The number of tests was higher than the
number of healthy subjects because plasma CA was measured
twice or even three times in several men at several weeks apart
to check the stability of the concentration with respect to time,
and was measured twice in several women to check for a
possible variation associated with the ovarian cycle. As far as
CA are concerned, no statistically significant difference was
computed between men and women, between women taking
and women not taking oral contraceptives, and in these two
latter subgroups, between the first and the second part of their
ovarian cycle. These data were pooled, and 70 tests represented
the control group.
Among the group of 35 CRFh, 18 volunteered to participate in
a second study, about three months later.
Protocols
Two studies were carried out. In the first study, data obtained
in 35 CRFh were compared to those obtained in control
subjects. A blood sample (5 ml) was collected from the arterio-
venous fistula in CRFh, through the catheter that would be used
during hemodialysis, and from a peripheral vein in control
subjects through a small inserted catheter. In either group, the
subjects were in recumbent position, and the blood sample was
obtained between 20 and 30 minutes after the minor stress
represented by the venous puncture.
Even though control subjects were fasting at the moment of
the blood sampling, this was not necessarily the case for all
patients. The "morning patients" (N = 16), thus called because
they were hemodialyzed between 0730 and 1130, were fasting,
while the "afternoon patients" (N = 20), hemodialyzed be-
tween 1330 and 1730 were not; they had taken their usual meal
between 1200 and 1300. There is no evidence to suspect an
effect of this difference upon the data obtained. As a matter of
fact, we have reported a lack of effect of an oral load of tyrosine
on plasma CA concentration in normal subjects [191. Further-
more if, as expected, the mean level of plasma tyrosine was
slightly higher in "afternoon patients" (75 mM, SEM = 5.4) than
in "morning patients" (67 mM, SEM = 4.2), this difference was
Patients with CR1
100 during hemodialysis(N = 18)
IN:
35( __
P 0.001 P < 0.001
Fig. 1. Recovery of internal standards of catecholamines, added to the
incubation medium of the radio—enzymatic assay, and expressed as a
percent of external standards in which unknown sample was replaced
by water.
not statistically significant, and none of these two means was
statistically different from mean tyrosine level in control sub-
jects (68 mM, SEM = 2.2). Lastly, no statistically significant
difference was computed between "morning patients" and
"afternoon patients" as far as plasma CA concentrations are
concerned; thus data of these two subgroups of patients were
pooled.
The second study was carried out in 18 patients to measure
the arterio-venous difference of CA, and the effects of hemodi-
alysis. A first series of samples (5 ml each) was obtained
between 60 and 90 minutes after the beginning of hemodialysis,
one sample on the arterial line, the other on the venous. The
dialysis membrane used was made of either polyacrylonitrile (N
= 11) or cuprophane (N = 7); the mean blood flow was 216
mI/mm (SEM = 4), and the mean ultrafiltration rate was 10.2
mI/mm (SEM = 1.2). In these conditions, and the patient being in
an apparently steady—state, a second series of blood samples
was obtained 125 minutes later (SEM = 5). The total volume of
blood taken was about 20 ml.
Patients, as well as control subjects, were volunteers after
complete explanation of the aim of the investigation, for which
approval of experimental design was given by INSERM.
Methods
CA were measured according to a radio-enzymatic tech-
nique, based upon that described by Peuler and Johnson [201,
with few modifications [19]. The methylation of CA, the basis of
the radio—enzymatic technique, can be reduced by several
factors which are still little known. As shown in Figure 1 the
recovery of internal standards, expressed as a percentage of
external standards, was about 75% in control subjects, and was
significantly below (about 40%) in CRFh. This apparent inhibi-
tion of catechol-O-methyltransferase, more marked in patients
than in controls, is in agreement with a recent study [21]. Figure
1 shows also that this apparent inhibition was significantly
lower on the venous than on the arterial side; this suggests that
Table 1. Causes of chronic renal insufficiency in 35 patients studied Internal vs. External Standards (= 100%)
Control
group
''
a No clinical sign of autononlic dysfunction was observed, but there
were irregular episodes of hypotension in three patients.
Patients
with
CAl
arterial
line
venous
line
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Table 2. Plasma catecholamine concentration, pg/mi
Control
subjects
Patients with
CR1 1'
Control Chronic renal
110 tests in 35 insufficiency
normal subjects) 135 patients)
Free catecho- N = 70 N = 35
lamines
a 1047
0 1021
800
Dopamine 31 5 61 14 <005 0
Norepinephrine 238 11 353 43 <0.01
Epinephrine 28 4 53 12 NS
Sulfo-conjugated N = 70 N 35
catecholamines
Dopamine 8068 571 151909 494i2 <0.001
Norepincphrine 2318 196 22892 2491 <0.001
Fpinephrine 3017 200 14072 3502 <0.001
Glucuro-conjugated N 11 N 20
catecholamines 600
°
Dopamine 20501 1791 19751 1938 NS
Norepinephrine 3243 462 3958 t 597 NS
Epinephrine 1743 336 4581 630 <0.001
----_______________ C
.2
0
00
this inhibition might be related on the presence of a poorly
0
°
dialyzable factor.
Conjugated CA were measured after enzymatic hydrolysis in
1/100 diluted plasma samples. Sulfo-conjugated CA were hy-
drolyzed by sulfatase (Sulfatase Type VI, Sigma, St Louis
Missouri, USA), according to Johnson's suggestion [22], while
.
glucuro-conjugated CA were hydrolyzed by glucuronidase (Be-
400t
.
C
,
8
— —
t
P-_0.001 0
ta-glucuronidase, Type IX, Sigma). The amount of glucuroni-
dase needed to hydrolyse glucuro-conjugated CA was empiri- — —
cally defined as the amount of enzyme that frees the largest
possible amount of CA from a sample of rat liver, after a 60
minute incubation at 37°C. This amount turned out to be 60
units/assay, which was halfway between the suggestion of
200 8
1%XJJ 8
o
Yoneda, Alexander and Vlachakis [23], and Claustre, Serusclat
and Peyrin [241. Normal values of plasma concentrations of
conjugated CA were greater than those previously reported, in
°
particular for data concerning glucuro-conjugated amines
[24—25]. Besides several differences in the methodology used,
our measurements were carried out on diluted samples. Why 0
the dilution of plasma samples has a so marked effect on the Fig. 2. Individual data jhr free NE obtained in control subjects and in
concentration measured, remains an unclear phenomenon; it patients wit/i CR1. It has to be noted that the NE level was higher than
has been observed for sulfo- and glucuro-conjugated CA, in
.
humans, dogs [19, 26], and guinea pig (personal unpublished
upper limit of normal subjects in S patients, and was below their lower
limit in 5 others.
data).
A spectrofluorimetric method [27] was used to measure
tyrosine, and a conventional photometric method to measure between patients (54.9), and controls (27.9). Five out of 35
creatinine. patients presented very high plasma NE concentration (Fig. 2)
Data are expressed as a mean, associated with SCM. Either with an increase of the level of DA and EPI in only two of them;
one—dimensional analysis of variance or Student's it-test were their individual age (22, 27, 31, 31, 40) was within the range of
used to test statistically significant differences. controls (21 to 49). Plasma concentration of free NE in the
group of 30 remaining patients, of mean age 52.7, was not
Results different from controls (273 +/— 28 vs. 238 +/— 11, Table 2).The statistical test does not supply us with all possible
Plasma concentration offree catecholamines in a large groap
.
oJ patients with CRFh
information provided by this study carried out on a rather large
group of patients. Figure 2 shows that the range of distribution
...of individual NE data in CRFh was apparently larger than in
In 35 non-selected patients whose renal diseases were of controls. A careful scrutiny of data disclosed that plasma NE
various origins (Table 1), a statistically significant increase of concentration of a majority of patients (25 over 35) was within
plasma concentration of dopamine (DA), and NE was ob- the range of distribution of controls, and we cannot rule out the
served, while that of epincphrine (EPI) was not different from existence of two subgroups of five patients each with either high
controls (Table 2). This was not related to the difference in age or low plasma free NE concentration. In the subgroup with high
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Table 3. Plasma concentration of creatinine, tyrosine, free and conjugated catecholamines measured twice at two hours apart during
hemodialysis in 18 patients (mean — first row, SEM — second row)
First series of measurement Second series of measurement
Arterial Venous V—A
line line duff.
Creatinine, mg/mi
109.4
7.4
Tyrosine, nmo!/mI
60.2
3.2
Free catecholamines, pg/mi
Dopamine
102
18
Norepinephrine
400
55
Epinephrine
52
9
Sulfo-conjugated catecholamines, pg/mi
Dopamine
58743
14383
Norepinephrine
16874
2273
Epinephrine
3685
430
165
28
—235
40
22
4
29
10
37892
13707
—20351
4012
6739
1123
—10000
1368
3117 557
343 305
Glucuro-conjugated catecholamines, pg/tn! (N = 10)
Dopamine
19540 21649 +2109
1081 1404 1212
Norepinephrine
3024 3126 +102
438 403 429
Epinephrine
2093
322
Arterial Venous V—A
line line duff.
79.4 29.8 50.7
6.0 3.1 4.2
59.2 34.0 24.6
5.2 3.1 2.9
Significantly different from the first measurement
NE, four patients were normotensive, and one was hyperten-
sive and treated with calcium antagonist plus diuretic.
Plasma concentration of conjugated CA in CRFh
As far as sulfo-conjugated CA are concerned, a tremendous
increase in their plasma level was observed (Table 2). It was
very predictable since it was observed in 33 out of 35 patients
for DA and NE sulfate, and in only 22 patients for EPI sulfate,
(the dividing line was the highest level measured in controls). It
is potentially important to record that neither in controls nor in
patients was a statistically significant correlation computed
between plasma concentrations of free CA and those of sulfo-
conjugated CA, between sulfo-conjugated themselves, or be-
tween either free or sulfo-conjugated CA and creatinine levels.
Lastly, data on Table 2 indicate a lack of difference in
glucuro-conjugated DA and NE between controls and patients.
The concentration of EPI glucuronate was significantly in-
creased in CRFh.
Effects of hemodialysis
Tyrosine, free and sulfo-conjugated CA were measured on
the arterial and on the venous line. All compounds but EPI
sulfate presented a venous concentration that was statistically
lower than their arterial (Table 3). Thus, various amounts of
these compounds were excreted by the artificial kidney; previ-
ous studies, mostly interested in free NE, have provided
contradictory conclusions 14, 7—9, 26]. As far as glucuro-
conjugated CA were concerned, no difference was measured
between the venous and the arterial line, in favor of their
non-elimination by the artificial organ.
It is potentially important to make a rough calculation1 of the
The estimate losses of tyrosine and of CA were calculated on the
basis of the mean arterio-venous difference (assuming that the two
series of measurements are representative of the hemodialysis pattern
for a given CA) and of the mean blood flow (216 mi/mm), and the usual
time of hemodialysis (four hours). Data are expressed in mg/ 4 hours.
P
39.2
2.8
—71.1
5.4
<0.001
33.0
2.0
—27.0
2.2
<0.001
72
13
—29
9
<0.01
<0.001
<0.01
<0.001
<0.001
113
21
90
19
—24
13
355
46
143
23
213
30
41
8
27
8
14
7
366l6
7075
23343
5562
—I4490
3109
9729
1423
4833
901
4948
743
3307
272
2868
226
21733
1738
20369
1808
P
<0.001
<0.001
<0.05
<0.001
<0.05
<0.00 1
<0.001
NS
NS
NS
NS
NS
NS
NS
NS2218
327
+ 124
264
487
257
—l370
1598
—278
270
—488
283
3351
523
2604
395
3073
573
2155
413
570 Cache ci al
(%) Dopanilne Norepinephrine
100
L
Fractional extraction
Fig. 3. Fractional extraction of catecholatnines calcalated in 18 pa-
dents according to the following formula: (A-V)/A CA/Creatinine x
100, where A and V represented the respective arterial and venoas
conceal rat ion of a given catecholamine. The fractional extraction of
tyrosine was 69% (sCM = 3). Symbols are: E, free; . sulfoconjugated.
amount of tyrosine and CA excreted through the artificial
kidney during a standard period of hemodialysis (four hours).
The so calculated losses of tyrosine were 242 mgI4 hr, while
those of free plus sulfo-conjugated CA were 0.96, 0.40, 0.02
mgI4 hr for DA, NE and EPI, respectively. Thus, the tyrosine
losses were about 200-fold larger than those of free plus
sulfo-conjugated CA.
Conseqaential effects of hetnodialysis on arterial
concentration of tyrosine, free and salfoconjugated CA
Measurements carried out on the arterial line at two hours
apart during hemodialysis showed (Table 3) the expected de-
crease of the concentration of creatinine, a lack of change of
that of tyrosine, and of free CA, and a significant decrease of
that of DA sulfate and NE sulfate; the decrease of EPI sulfate
was not significant. Since the arterio-venous difference of
tyrosine and free CA were unchanged, the decrease of their
arterial concentration must imply that the losses induced by the
artificial kidney have been replaced. As far as sulfo-conjugated
CA are concerned, both arterial concentration and arterio-
venous difference of DA and NE sulfate were significantly
reduced, while they were unchanged for EPI sulfate.
Fractional extraction (FE) of cateciwlatnines
FE were calculated because the handling of CA by the
artificial kidney may have a role on their arterial concentration.
Since no difference was computed between patients hemodia-
lyzed with a polyacrylonitrile membrane (N = II) and those
hemodialyzed with a cuprophane membrane (N = 7), data
Epinephrine obtained were pooled. Results are presented in Figure 3. There
was no significant difference between the FE of free DA and
that of DA sulfate, neither between the FE of free NE and that
of NE sulfate; the FE of EPI sulfate was significantly below that
of free EPI. Thus, the difference between free DA and NE and
sulfo-conjugated DA and NE reported in the previous para-
graph was not related to a difference in the handling of these
four compounds by the artificial kidney. On the contrary, the
apparently low FE of EPI sulfate could account for the lack of
statistically significant change of its arterio-venous difference,
and thus its arterial concentration after a two hour period of
hemodialysis.
Incidentally, Figure 3 shows that the FE of the six forms of
CA measured was usually below 100%, suggesting that their
elimination by the artificial kidney was less efficient than that of
creatinine. The artificial kidney seems to be more efficient in
eliminating NE than DA of which the FE was statistically
different.
Discussion
The first goal of the present study was to measure plasma CA
concentration in patients with chronic renal failure, and
hemodialyzed for various periods of time. 'l'his topic was worth
viewing in a large group of patients because previous studies
have reported conflicting conclusions [1—101. Plasma NE levels
were usually obtained in small groups of patients, and data
might disagree because they covered different segments of an
heterogenous population, as already suggested by clinical ob-
servations. Thus, all patients regularly hemodialyzed in our
medical center, and representing a group of 35 non-selected
patients entered this study. Taken as a whole, our data (Table 2)
demonstrated a statistically significant increase of free DA and
free NE, while free EPI was not changed, as already shown for
NE [1—61. However, a statistically significant difference does
not provide the totality of the information; a careful scrutiny of
individual data (Fig. 2) disclosed that plasma NE concentration
of 25 out of 35 patients was within the limits of distribution of
controls, while it was higher in five patients, and lower in
another subgroup of five. According to this subgrouping, based
on plasma NE concentrations, one may wonder whether sub-
groups of patients with either hyper-, normo- or hypo-activity
of their adrenergic nervous system could exist in CRFh, assum-
ing that plasma NE concentration is a good index. Our study
cannot answer this question; neither it can rule out that the
consequential effect of the artificial kidney on the level of
plasma NE concentration might vary from one patient to
another.
The second aim of the present study was to measure the
plasma concentration of conjugated CA with the hope of
identifying a more reliable index of the adrenergie activity; in
the light of present knowledges, that goal was not reach. Our
data demonstrate a tremendous increase in the plasma level of
sulfo-conjugated CA in patients with CRFh, while plasma
concentration of glucuro-conjugated DA and NE was not dif-
ferent from controls (Table 2). This is a new observation. The
increase of sulfo-conjugatcd CA was not only very great, hut
also very predictable since it was observed in 33 out of 35
patients for DA sulfate and NE sulfate. This feature seems to be
independent of the origin of the renal disease, independent of
the presence (N = 15) or the absence (N = 20) of a residual
0
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diuresis, independent of the presence (N = 17) or of the absence
of hypertension (N = 18), and does not seem to be related to the
level of free CA since there was no statistically significant
correlation between free and sulfo-conjugated amines. This
observation is thus difficult to assess at the present time. That
such an increase was a reflection of a ANS hyperactivity,
hyperactivity that would have been almost totally offset by an
increased activity of the sulfo-conjugating process, seems to be
a remote possibility. A tentative investigation could be oriented
towards a more or less specific retention of sulfo-conjugated
CA. However, the fractional extraction of DA sulfate and NE
sulfate was not different from that of their free congeners (Fig.
3); thus the very high level of DA and NE sulfate concentration
cannot be explained by a difference in their handling by the
artificial kidney. Furthermore, it seems rather surprising that no
significant correlation was computed between plasma sulfocon-
jugated CA and plasma creatinine level, since an highly signif-
icant correlation between sulfate and creatinine was reported in
CRFh [181. Thus, the mechanism(s) responsible for the large
increase of the level of sulfo-conjugated CA in CRFh, associ-
ated with a lack of change of glucuro-conjugated DA and NE,
remain(s) to be investigated; so it is for the small, but statisti-
cally significant increase of EPI glucuronide.
The third goal of our study was to measure tyrosine, free and
conjugated CA on the arterial and the venous line of the
artificial kidney in order to evaluate their artificial elimination.
As shown in Table 3, a highly significant difference was
measured for tyrosine free CA, and sulfo-conjugated DA and
NE, in favor of their elimination by the artificial kidney. The
arterio-venous difference of EPI sulfate was not statistically
significant; this might be related to its low fractional extraction
(Fig. 3). Lastly, no difference was measured for glucuro-
conjugated CA, suggesting that they were poorly, if any,
eliminated by the artificial kidney.
A rough estimate of tyrosine and CA losses during a standard
period of hemodialysis (four hours) disclosed that tyrosine
losses were about 200-fold greater than CA losses. This might
turn out to be an important point, since an increase of tyrosine
was shown to induce an increase of CA synthesis [291. It is
reasonable to speculate that a decrease of tyrosine could be
associated with a decrease of CA synthesis. Thus, the hemodi-
alysis—induced losses of tyrosine might have a much greater
physiological effect on the adrenergic nervous system, and
possibly on blood pressure regulation, than losses of CA.
Finally, the consequential effect of the artificial kidney was
investigated by measuring plasma CA concentration at two
hours apart during a standard period of hemodialysis.
As far as tyrosine and free CA are concerned, their arterial
concentration and their arterio-venous difference were not
changed by two hours of hemodialysis. The interpretation of
this observation remains speculative at the present time. It
needs to consider a system with three compartments: the
hemodialysis bath where these four compounds are collected,
the intravascular compartment, and a third one that should
provide tyrosine, and free CA in such amounts that their arterial
concentrations were kept unchanged, even though they were
continually eliminated through the artificial kidney. We have
obviously no information on this third compartment except to
wonder whether it could be the adrenergic tissue for free CA.
The discussion of DA sulfate and NE sulfate variations
during hemodialysis is, at first glance, not so complicated. The
decrease of their arterial concentration, and of their arterio-
venous difference prompted us to consider a transfer from the
vascular compartment to the hemodialyzing bath. If true,
plasma DA sulfate and NE sulfate level should tend towards the
normal level if the hemodialysis time is increased.
In conclusion, our data demonstrated a increase of plasma
concentration of free DA and free NE in patients with CRFh,
while their free EPI concentration was not different from
controls. However, a careful scrutiny of 35 individual data
suggests that subgroups of patients with either high, normal, or
low plasma NE concentration could exist. In these patients,
there was a large and usually predictable increase of sulfo-
conjugated CA concentration, while that of glucuro-conjugated
DA and NE was unchanged, and that of glucuro-conjugated EPI
was increased. This demonstrates that conjugated CA are
partially altered in CRFh, but neither the cause nor the physi-
ological meaning, if any, of this alteration can be assessed at the
present time. As far as hemodialysis is concerned, an arterio-
venous difference was observed for tyrosine and for free CA
and sulfo-conjugated DA and NE, demonstrating their elimina-
tion by the artificial kidney. Since the amount of tyrosine
eliminated was about 200-fold greater than that of free and
sulfo-conjugated CA, a double series of effects of hemodialysis
on CA metabolism can be suspected: a) by reducing their
circulating level, and b) by reducing the amount of tyrosine
available, and thus the amount of CA synthesized. Although
tyrosine and free CA were continually eliminated through the
artificial kidney during a two hour period of time, their arterial
concentrations were not changed, while that of DA sulfate and
NE sulfate was significantly reduced. Thus the organism does
not seem to handle in the same manner free and sulfo-conjuga-
ted CA.
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